Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Assets per Share

The Total Assets per Share of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Nov 3, 2026 is 16.04 CNY. In the previous year, Total Assets per Share was 19.19 CNY — a change of -16.40% (lower).

Assets per Share

16.04CNY

YoY

-16.40%

Last updated:

Total Assets per Share of Tibet Duo Rui Pharmaceutical Co is 2025 16.04 CNY. Total Assets per Share of Tibet Duo Rui Pharmaceutical Co was 2024 19.19 CNY. It decreases by -16.40% lower compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
2.93 CNY
Jan 1, 2019
3.68 CNY
Jan 1, 2020
4.66 CNY
Jan 1, 2021
10.64 CNY
Jan 1, 2022
11.24 CNY
Jan 1, 2023
13.40 CNY
Jan 1, 2024
19.19 CNY
Jan 1, 2025
16.04 CNY
The Tibet Duo Rui Pharmaceutical Co Assets per Share history
YEARAssets per ShareYoY
16.04CNY-16.40%
19.19CNY+43.15%
13.40CNY+19.29%
11.24CNY+5.57%
10.64CNY+128.28%
4.66CNY+26.75%
3.68CNY+25.36%
2.93CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Total Assets per Share of Tibet Duo Rui Pharmaceutical Co is 16.04 CNY in 2025.

Total Assets per Share of Tibet Duo Rui Pharmaceutical Co changed from 19.19 CNY to 16.04 CNY, representing a -16.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co